Company intelligence / Profile preview
OGRD Alliance
Orlando, Florida, United States
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
The company's lead immunotherapy platform, PLPC-DB, has demonstrated clinical utility in reprogramming the tumor microenvironment with low toxicity, supported by over a decade of real-world evidence (RWE) from the OncoVix program in Latin America and presentations at major oncology congresses including ASCO and ESMO.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Non-cellular immunobiological platformVesicle-based therapyExosome-based therapyNutraceutical
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Flowinmunocell-Bioexocell GroupBioclas
Beyond the preview
Go deeper on OGRD Alliance.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OGRD Alliance.